SCHEMBL6208030

SCHEMBL6208030

CCc1c(NC(=O)c2cc(S(=O)(=O)N3CCN(CC)CC3)ccc2Cl)c(C(N)=O)nn1Cc1ccccn1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.54
PDE5A O76074 4/20 0.51
APOBEC3A P31941 3/20 0.49
APOBEC3G Q9HC16 3/20 0.49
LMNA P02545 2/20 0.49
USP2 O75604 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
PKM P14618 1/20 0.49
PABPC1 P11940 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
PDE6C P51160 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6332580 0.90 PDE5A (0.57) KMT2APDE5AAPOBEC3AAPOBEC3GNPC1
SCHEMBL6200638 0.87 PDE5A (0.68) KMT2APDE5APKMALDH1A1KDM4E
SCHEMBL6447294 0.86 PDE5A (0.52) KMT2APDE5ANPC1RAB9APKM
SCHEMBL6200684 0.86 PDE5A (0.60) KMT2APDE5APDE6C
SCHEMBL6444896 0.82 PDE5A (0.62) KMT2APDE5AALDH1A1KDM4EPDE6C
SCHEMBL6444195 0.81 PDE5A (0.56) KMT2APDE5APKMALDH1A1KDM4E
SCHEMBL6443153 0.81 PDE5A (0.55) KMT2APDE5AAPOBEC3AAPOBEC3GALDH1A1
SCHEMBL6446019 0.81 PDE5A (0.55) KMT2APDE5AAPOBEC3AAPOBEC3GALDH1A1
SCHEMBL6446584 0.80 PDE5A (0.55) KMT2APDE5AALDH1A1KDM4EPDE6C
SCHEMBL7003161 0.80 PDE5A (0.62) KMT2APDE5ASMN1; SMN2NPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0994115-B1 Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof PFIZER LTD (GB) 2005-03-02 EP disclosed
US-20030069422-A1 Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof DUNN PETER JAMES (GB) 2003-04-10 US disclosed
US-6207829-B1 CYCLIZATION OF A CORRESPONDING PYRAZOLE COMPOUND PFIZER INC. 2001-03-27 US disclosed
EP-0994115-A2 Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof Pfizer Limited (GB) 2000-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069422-A1 Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof UGT2B7, CYP3A7, TOP2B KMT2A 2876/4885PDE5A 1483/4885APOBEC3A 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.